Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Leukemia 8Leukemia, Myeloid, Acute 6Congenital Abnormalities 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic Syndromes 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Hodgkin Disease 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Intraocular Lymphoma 2

Interventions

fludarabine phosphate 6Cytarabine 6Peripheral Blood Stem Cell Transplantation 4Etoposide 4Busulfan 4Hydroxyurea 3Filgrastim 3Decitabine 3Cyclophosphamide 3romidepsin 2laromustine 2Vorinostat 2Tretinoin 2Sunitinib 2Radiotherapy 2Methotrexate 2Ipilimumab 2Idarubicin 2Daunorubicin 2CTLA-4 Antigen 2Antilymphocyte Serum 2Analgesia 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2veliparib 1valspodar 1tipifarnib 1perifosine 1gamma-Globulins 1belinostat 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative × laromustine × Clear all
NCT00049686 2013-07-18

VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00083187 2013-07-18

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

National Cancer Institute (NCI)

Phase 2 Completed
230 enrolled
MyeloidOther hematologic neoplasm

Congenital Abnormalities, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡